
|Videos|April 21, 2017
Acquired Resistance to Osimertinib in T790M-Positive NSCLC
Author(s)Geoffrey R. Oxnard, MD
Geoffrey R. Oxnard, MD, discusses a study that found overgrowth of competing resistance mechanisms, such as an acquired <em>KRAS</em> mutation, underlies a poor prognosis subtype of acquire resistance to osimertinib in T-790M-positive non-small cell lung cancer.
Advertisement
Geoffrey R. Oxnard, MD, assistant professor of Medicine, Dana-Farber Cancer Center, Harvard Medical School, discusses a study that found overgrowth of competing resistance mechanisms, such as an acquiredKRAS
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Rethinking Advanced Prostate Cancer: Surprising Finds from a Landmark Study
2
Long-Term Follow-Up Confirms Benefits of Low-Dose Seminoma Treatment
3
FDA Accepts NDA for 177Lu-edotreotide in GEP-NETs
4
FDA Authorizes EXENT System to Aid Myeloma Diagnosis
5









































